Shattuck Labs, Inc.
NASDAQ:STTKBiotechnology
+$0.11 today
- Market cap
- $455.24M
- Beta
- 1.09
- P/E (TTM)
- -10.9
- EPS (TTM)
- -$0.44
Volume 2.08M
Average 0.69M
STTK Total Current Liabilities
All obligations due within one year.
Shattuck Labs, Inc.NASDAQ: STTK
Total Current Liabilities · Q1 FY2026 · quarter ended Mar 2026
Total current liabilities falls 41.9% from a year ago
Total current liabilities stood at $4.25M at the end of Q1 FY2026, down 41.9% from a year earlier and down 39.7% from the prior quarter. Over 3 fiscal years it compounded at -34.4% a year.
Context
- Total current liabilities amounted to 4.2% of total assets at the end of Q1 FY2026, down 5.3 pp from a year earlier.
- Total current liabilities increased in 0 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether total current liabilities keeps falling in the next quarterly balance sheet after a -41.9% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Current Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 7.05M USD
- Year-over-year change
- -20.9%
- 4-year CAGR
- -26.8%
| Period | Period end | Total Current Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 7.05M | -20.9% |
| FY2024 | 2024-12-31 | 8.92M | -22.1% |
| FY2023 | 2023-12-31 | 11.45M | -54.1% |
| FY2022 | 2022-12-31 | 24.97M | +1.5% |
| FY2021 | 2021-12-31 | 24.59M | — |
Total Current Liabilities vs competitors
How STTK compares with its peers on the latest reported figures
- STTK's Mar 2026 total current liabilities of $4.25M is the 8th highest of the 10 companies compared; the peer median is $10.15M.
- Its year-over-year change of -41.9% is the 7th highest of 10, against a peer median of -15.9%.
- Total current liabilities amounts to 4.2% of total assets for STTK, versus a peer median of 10.7%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Sep 2026 | $105.77M | -15.9% | +14.8% | 10.7% | |
| Mar 2026 | $59.74M | -31.1% | +1.6% | 31.0% | |
| Mar 2026 | $14.53M | -13.7% | +1.0% | 10.9% | |
| Mar 2026 | $14.19M | +442.4% | +59.6% | 7.1% | |
| Mar 2026 | $10.15M | -44.4% | -1.2% | 41.1% | |
| Jun 2026 | $9.58M | +147.4% | -22.3% | 5.1% | |
| Sep 2026 | $9.29M | +56.7% | -23.2% | 6.6% | |
| Mar 2026 | $4.25M | -41.9% | -34.4% | 4.2% | |
NBPNovaBridge Biosciences | Dec 2025 | $3.84M | -93.8% | -82.0% | 10.3% |
| Mar 2026 | $933K | -64.3% | +21.5% | 42.8% | |
| Peer median (excluding STTK) | $10.15M | -15.9% | +1.0% | 10.7% | |
Competitors are the stored peer set for STTK. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 92.27M | 47.38M | 125.63M | 57.39M | 54.19M |
| Short-term Investments | 176.54M | 113.9M | 5M | 15.6M | 23.87M |
| Net Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 0 | 23.3M | 12.6M | 6.23M | 4.41M |
| Total Current Assets | 288.27M | 184.58M | 143.22M | 79.22M | 82.48M |
| Property, Plant & Equipment (Net) | 9.94M | 17.67M | 13.8M | 9.81M | 6.11M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 0 | 0 | 0 | 0 | 1M |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 381K | 3.07M | 2.54M | 2.02M | 1.44M |
| Total Non-current Assets | 10.32M | 20.74M | 16.34M | 11.83M | 8.55M |
| Total Assets | 298.59M | 205.32M | 159.56M | 91.05M | 91.03M |
| Account Payables | 10.01M | 7.17M | 1.59M | 2.42M | 2.1M |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 11.25M | 5.84M | 4.84M | 2.7M | 3M |
| Total Current Liabilities | 24.59M | 24.97M | 11.45M | 8.92M | 7.05M |
| Long-term Debt | 0 | 0 | 0 | 0 | 1.58M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 2.21M | 0 | 0 | 0 | 0 |
| Total Non-current Liabilities | 2.21M | 4.2M | 3.41M | 2.51M | 1.58M |
| Total Liabilities | 26.8M | 29.17M | 14.86M | 11.42M | 8.64M |
| Common Stock | 5K | 5K | 5K | 5K | 7K |
| Retained Earnings | (117.07M) | (219.01M) | (306.31M) | (381.72M) | (430.53M) |
| Accumulated OCI | (560K) | (877K) | 4K | 2K | 6K |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 271.79M | 176.16M | 144.71M | 79.63M | 82.39M |
| Total Debt | 0 | 4.9M | 4.2M | 3.41M | 2.42M |
| Net Debt | (92.27M) | (42.48M) | (121.42M) | (53.98M) | (51.77M) |
Shattuck Labs, Inc.
NASDAQ:STTK
Intrinsic Alpha fair value
Locked
Current Price
$4.47
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.